Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2008

View Archived Issues

Pfizer compounds reveal potential of c-Met inhibition for cancer treatment

Deciphera describes activity and optimization of bcr-Abl kinase inhibitor DCC-2036

Novel therapeutic agents for cancer covered in recent patent literature

Bristol-Myers Squibb develops a novel and potent statin with reduced myotoxicity

Org-52186 shows potential for treating anxiety and depression

Preclinical data on Pfizer's alpha2delta ligand PD-0200390 reported

Cleveland BioLabs completes enrollment in phase II clinical trial of Curaxin in prostrate cancer

Dutch health authorities license Vaccinogen to manufacture OncoVAX anticolon cancer vaccine

Cytopia and Cancer Therapeutics enter anticancer drug development collaboration

Dainippon Sumitomo initiates phase I clinical development of immune response modifier

iCo Therapeutics acquires worldwide rights to iCo-009 for systemic fungal infections

Microbix forms Klarogen Biotherapeutics and acquires ImaRx's clot busting drug urokinase

Mistral Pharma not to pursue combination with U.S. specialty pharmaceutical company

OrthoLogic reports positive safety data from phase I clinical trial of AZX-100

Endogenous inhibitor of corneal lymphangiogenesis shows potential in corneal transplantation model

Dana-Farber Cancer Institute initiates phase I trial of EntreMed's ENMD-2076

New class of topical antioxidants for the treatment of retinal disorders reported by Sirion

FDA grants approval to Osiris for expanded access treatment program for Prochymal in GVHD

BiPar expands phase II clinical trial programs for BSI-201 to include ovarian cancer

FDA approves Strattera for maintenance of ADHD in children and adolescents

Recent patents disclose new agents for endocrine disorders

FDA grants orphan drug designation for palifosfamide in soft tissue sarcoma

Medarex initiates phase II trials in ulcerative colitis and rheumatoid arthritis

Active Biotech moves Anyara into phase III in renal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...